News

In a recent phase 2 trial, abatacept failed to significantly reduce progression to diabetes or abnormal glucose tolerance among a cohort of stage 1 relatives of people with type 1 diabetes considered to be at risk of progression.

The mean change from baseline to the day of the first masked gluten challenge in total gastrointestinal scores for the non-homozygous Nexvax2 group was 2.86 compared to 2.63 for the non-homozygous placebo group.

In research drawn from his conference presentation, Lim discussed the unique photoprotection needs of skin of color as well as some of the challenges faced by patients in this population.

An analysis of more than 500,000 pregnancies over a 15-year period suggests much of the increase in gestational diabetes rates observed during the study period can be attributed to changes in screening practices.

A small molecule IL-17A inhibitor, izokibep has additionally shown efficacy in treating psoriatic arthritis—and will now be reviewed in a phase 3 HS trial.

Pediatric dermatologist Mercedes Gonzalez, MD, discusses the new phase 3 B-SIMPLE data supporting berdazimer gel as the first potential molluscum treatment.

Kwatra spoke about his team’s research into nemolizumab for prurigo nodularis in the OLYMPIA 2 trial, including the data and its implications for the future.

New data indicates that an oral TYK2 inhibitor known as NDI-034858 showed strong results for psoriasis patients in a recent phase 2b trial.

New data has indicated that patients with psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor.

In a new interview, Eichenfield discussed the background of his presentation on late-breaking data from the INTEGUMENT-1 and INTEGUMENT-2 trials on roflumilast for atopic dermatitis.

New phase 3 data from the BRAVE-AA trial program showed some patients who had little response to initial baricitinib achieved hair growth in year 2 of treatment.

Late-breaking phase 3 data on nemolizumab monotherapy indicates substantial improvement in key primary and secondary endpoints for prurigo nodularis patients.

The Icahn investigator reviews new data suggesting ethnicity-based differences in molecular phenotype of atopic dermatitis, which may better inform treatment strategies for different populations.

Late-breaking data showed strong results for ruxolitinib cream as a treatment for vitiligo in the long-term extension of the TRuE-V1 and TRuE-V2 studies.

New phase 3 DELTA 1 trial data show the topical pan-JAK inhibitor doubled the rate of treatment success versus vehicle cream.

New late-breaking data showed positive results from the phase 2 trial on a novel septa-specific monoclonal antibody for HS patients.

Dupilumab showed strong results for uncontrolled moderate-to-severe hand and foot atopic dermatitis, meeting its primary and secondary endpoints in the trial.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

In this interview segment, Kwatra describes his upcoming conference presentation on prurigo nodularis and some of the biggest takeaways from his presentation.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

Three years into the pandemic, dermatologists have become more confident in discussing vaccine issues with their patients, including the misunderstood risk of disease flare-up associated with boosters.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Personalized text message-based smoking cessation intervention was found to be more effective than the non-personalized text message approach, especially among smokers with low nicotine dependence and strong quitting intention.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

An interview segment with Lim in which he describes some key takeaways from his conference presentation on sunscreen, photoprotection, and phototherapy.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

An investigation utilizing machine learning (Recursive Ensemble Feature Selection, REFS) identifies potential biomarkers for asthma control in pediatric patients.

In his conference presentation ‘Phototherapy and Photoprotection,’ Lim describes some key takeaways and research on UV filter and photoprotection health effects.